PLN formulations have been known to induce tremendous enhancement in the efficacy of doxorubicin and mitomycin C through the inhibition of breast cancer resistance protein (BCRP+) and multidrug resistance protein 1 (MRP1+), which are overexpressed in many human breast cancer cells [17,37,38]. This evidence concerns the gene ABCG2 and breast carcinoma.